Differential Effects of Simvastatin and Atorvastatin on High-Density Lipoprotein Cholesterol and Apolipoprotein A-I Are Consistent across Hypercholesterolemic Patient Subgroups

Clinical Cardiology

Volumn 26, Issue 11, 2003, Pages 509-514

  Davidson, Michael H ^a   Ose, Leiv ^b   Frohlich, Jiri ^c   Scott, Russell S ^d   Dujovne, Carlos A ^a   Escobar, Ivan D ^e   Bertolami, Marcelo C ^f   Cihon, Frank ^g   Maccubbin, Darbie L ^g   Mercuri, Michele ^g  

^a RADIANT RESEARCH   (United States)

^b Lipidklinikken   (Norway)

^c ST PAUL S HOSPITAL   (Canada)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

^e Association Colombiana de Diabetes   (Colombia)

^f INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apolipoprotein A I; Atorvastatin; High density lipoprotein; Simvastatin; Statins

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 10744232357     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960261106     Document Type: Article

References (27)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendöffer A, Stein EA, Kruyer W, Gotto AM Jr, for the AFCAPS/ TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. J Am Med Assoc 1998;279:1615-1622
3. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
4. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in participants with average cholesterol levels. N Engl J Med 1996;335:1001-1009
5. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A: Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results of the LIPID trial. Ann Intern Med 2001; 134:931-940
6. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;360:7-22.
7. Rosenson RS, Tangney CC: Antiatherothrombic properties of statins: Implications for cardiovascular event reduction. J Am Med Assoc 1998;279: 1643-1650
8. White MC: Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 1999;39:111-118
9. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-431
10. Crouse JR, Frohlich J, Ose L, Mercuri M, Tobert JA: Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 1999;83:1476-1477
11. Illingworth DR, Crouse JR III, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB, for the Simvastatin Atorvastatin HDL Study Group: A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2002;17:43-50
12. Kastelein JJP, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB: Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000;86:221-223
13. Recto CS, Acosta S, Dobs A: Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. Clin Cardiol 2000;23:682-688
14. Wilson PWF: High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol 1990;66:7A-10A
15. Manninen V, Kostinen P, Manttari M. Huttunen JK, Canter D. Frick HM: Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Frederickson type IIa subjects in the Helsinki Heart Study. Am J Cardiol 1990;66:24A-27A
16. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989;79:8-15
17. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-418
18. Mikhailidis DP, Wierzbicki AS: HDL Cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000;16:139-146
19. Wierzbicki AS, Lumb PL, Chik G, Crook MA: High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol 2000;86:547-549
20. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study), Am J Cardiol 1998;81:582-587
21. Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, Black D: A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39-44
22. Farnier M, Portal J-J, Maigret P: Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther 2000;5:27-32
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2000;285:2486-2497
24. Timar O, Sestier F, Levy E: Metabolic syndrome X: A review. Can J Cardiol 2000;16:779-789
25. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. J Am Med Assoc 2002;287:356-359
26. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-3051
27. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847